國家衛生研究院 NHRI:Item 3990099045/2843
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 864360      Online Users : 526
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/2843


    Title: Low-dose thalidomide treatment for advanced hepatocellular carcinoma
    Authors: Hsu, C;Chen, CN;Chen, LT;Wu, CY;Yang, PM;Lai, MY;Lee, PH;Cheng, AL
    Contributors: National Institute of Cancer Research
    Abstract: Objective: To analyze the efficacy of oral thalidomide in the treatment of advanced hepatocellular carcinoma ( HCC). Methods: Sixty- eight patients with unresectable and nonembolizable HCC were consecutively enrolled in a compassionate treatment program of oral thalidomide. Tumor response and treatment- related toxicity were prospectively followed. Thalidomide was given at a starting dose of 200 mg per day. The dose was gradually escalated in 100- mg steps up to 600 mg per day if no limiting toxicities developed. Results: Sixty- three patients were evaluable for response. One complete and 3 partial responses, defined by World Health Organization criteria, were seen, with a response rate of 6.3% ( 95% CI 0 - 12.5). The duration of response was 50+, 24.6, 11.6+ and 8.7+ weeks, respectively. All 4 responders had a dramatic decrease in alpha- fetoprotein ( alpha- FP) levels. Another 6 of the 42 patients with elevated alpha- FP levels before treatment had a more than 50% decrease in their alpha- FP levels after thalidomide treatment. Totally 10 patients had an objective response to thalidomide. The median overall survival for all of the 68 patients was 18.7 weeks ( 95% CI 11.8 - 25.6) with a 1- year survival rate of 27.6%. The median overall survival of the 10 patients with an objective response to thalidomide was 62.4 weeks ( 95% CI 31.2 - 93.6 weeks). All responders responded at a dose equal to or less than 300 mg per day. Toxicities of thalidomide were generally manageable, and only 16, 6, and 0 patients developed grade 2, 3, and 4 toxicities, respectively. Conclusion: Low- dose thalidomide is safe and induces unequivocal tumor response in a minority of patients with advanced HCC.
    Keywords: Oncology
    Date: 2003
    Relation: Oncology. 2003;65(3):242-249.
    Link to: http://dx.doi.org/10.1159/000074477
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0030-2414&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000186975500008
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0344305652
    Appears in Collections:[Li-Tzong Chen] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    000186975500008.pdf216KbAdobe PDF380View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback